Precision Business Insights


Immuno Oncology Drugs Market

: Global Market Estimation, Dynamics, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

The Global Immuno Oncology Drugs Market: Immuno Oncology Drugs By Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Others) By Application (Breast Cancer, Blood cancer, Liver Cancer, Brain cancer, Colorectal Cancer, Others) By End Users (Hospitals, Ambulatory Centers, Clinics, Academic Institutes), By Geography


Immuno Oncology Drugs Market


Market Outline: Global Immuno Oncology Drugs Market 

Immuno-oncology includes utilization of patients’ safe framework to battle against disease. Immuno-oncology utilizes novel immunotherapies that lift the invulnerable arrangement of patients. These treatments focus on the insusceptible arrangement of the body rather than the tumors and empower the invulnerable framework to perceive and target malignancy cells. Immuno-oncology does not influence the working of solid cells instead of regular treatments, for example, chemotherapy and radiation treatment. Long haul reaction can be created with the assistance of these treatments as they give dependable memory to the resistant framework. Resistant framework adjusts to the malignancy after some time and gives long haul reaction to the growth.


Market Dynamics: Global Immuno Oncology Drugs Market 

The market growth of immuno oncology drugs is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, immuno oncology drugs are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of immuno oncology drugs, are fueling the sales revenue of immuno oncology drugs market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of immuno oncology drugs market.


Market Scope: Global Immuno Oncology Drugs Market 

The Global Immuno Oncology Drugs Market is classified on the basis of type, application, end user, and geographical regions.

Based on Application, Global Immuno Oncology Drugs Market is segmented as

  • Breast Cancer
  • Blood cancer
  • Liver Cancer
  • Brain cancer
  • Colorectal Cancer
  • Others

Based on Type, Global Immuno Oncology Drugs Market is segmented as

  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • Immune System Modulators
  • Cancer Vaccines
  • Others


North America

  • US
  • Canada


  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe


  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Based on the End-user, Global Immuno Oncology Drugs Market is segmented as

  • Hospitals
  • Ambulatory Centers
  • Clinics
  • Academic Institutes


Market Summary: Global Immuno Oncology Drugs Market 

Currently immuno oncology drugs market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. Producers are concentrating on redesigning the accessible resistant oncology tranquilizes and in addition growing new safe oncology drugs for tumor treatment. For example, AstraZeneca’s Durvalumab (Imfinzi) was affirmed in 2017, as invulnerable checkpoint inhibitor, which squares cooperation of PD-L1 with PD-1 and CD80. In December 2017, Bristol-Myers Squibb got endorsement for Nivolumab (Opdivo) in adjuvant treatment of melanoma. In August 2017, Novartis got endorsement for CAR-T treatment named Kymriah for youngsters and youthful grown-up with B-cell lymphoblastic lymphoma. Gilead Life Science finished the securing of Kite pharma Ltd. in October 2017, and Gilead’s CAR-T treatment Yescarta got the U.S. Nourishment and Drug Administration (FDA) endorsement in October 2017 to treat non-Hodgkin lymphoma. Celgene Corporation, in January 2018, reported obtaining of Juno Therapeutics, Inc. Through this obtaining, Celgene Corporation will access novel CAR-T treatment, which is in pipeline of Juno Therapeutics. Moreover, Amgen, Inc. gotten FDA endorsement, for Imlygic in 2017, which is an oncolytic infection to treat melanoma. In March 2017, Avelumab (Bavencio), mutually created by EMD Serono, and Pfizer, Inc. gotten FDA endorsement for the treatment of metastatic merkel cell carcinoma. . In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets.


Regional Analysis: Global Immuno Oncology Drugs Market 

Geographically Global Immuno Oncology Drugs Market is segmented as Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe.  North America immuno oncology drugs market growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing immuno oncology drugs among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of immuno oncology drugs in treatment of cancer. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the immuno oncology drugs in Latin-America.

Market participants: Global Immuno Oncology Drugs Market 

Some of the players in Global Immuno Oncology Drugs Market

  • Merck & Co. Inc. (U.S.)
  • Hoffmann-La Roche AG (Switzerland)
  • Spectrum Pharmaceuticals U.S.)
  • Eli Lilly and Company (U.S.)
  • Amgen Inc. (U.S.)
  • Bristol-Meyer Squibb (U.S.)
  • Sanofi S.A. (France)
  • AstraZeneca plc (U.S.)
  • 3M Company (US)
$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
Single User $ 4,400.00
Multiple User $ 6,600.00
Corporate User $ 8,900.00
buy now spinner

Our Clients